nach oben

Pathology & Oncology Research

Erschienen in:

01.09.2011 | Research

Glucocorticoid Receptor Expression and Antiproliferative Effect of Dexamethasone on Human Melanoma Cells

verfasst von: Judit Dobos, István Kenessey, József Tímár, Andrea Ladányi

Erschienen in: Pathology & Oncology Research | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Glucocorticoids, such as dexamethasone are widely used in cancer therapy and have cell type-specific pro- or antiapoptotic effects. We examined whether melanoma cells are sensitive to dexamethasone treatment. We have demonstrated for the first time that in human melanoma cell lines as well as in benign and malignant melanocytic tumors glucocorticoid receptor (GCR) is present both at mRNA and protein level. Dexamethasone applied at high doses inhibited the in vitro growth of WM983A human melanoma cells. The inhibitory effect was due to apoptosis induction. In the case of this relatively sensitive cell line dexamethasone enhanced the effect of the chemotherapeutic drug DTIC.

Herr I, Gassler N, Friess H et al (2007) Regulation of differential pro- and anti-apoptotic signaling by glucocorticoids. Apoptosis 12:271–291PubMedCrossRef

Kogianni G, Mann V, Ebetino F et al (2004) Fas/CD95 is associated with glucocorticoid-induced osteocyte apoptosis. Life Sci 75:2879–2895PubMedCrossRef

Wang Z, Malone MH, He H et al (2003) Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. J Biol Chem 278:23861–23867PubMedCrossRef

Abrams MT, Robertson NM, Yoon K et al (2004) Inhibition of glucocorticoid-induced apoptosis by targeting the major splice variants of BIM mRNA with small interfering RNA and short hairpin RNA. J Biol Chem 279:55809–55817PubMedCrossRef

Zhang L, Insel PA (2004) The pro-apoptotic protein Bim is a convergence point for cAMP/protein kinase A- and glucocorticoid-promoted apoptosis of lymphoid cells. J Biol Chem 279:20858–20865PubMedCrossRef

Oshima Y, Kuroda Y, Kunishige M et al (2004) Oxidative stress-associated mitochondrial dysfunction in corticosteroid-treated muscle cells. Muscle Nerve 30:49–54PubMedCrossRef

Necela BM, Cidlowski JA (2004) Mechanisms of glucocorticoid receptor action in noninflammatory and inflammatory cells. Proc Am Thorac Soc 1:239–246PubMedCrossRef

Beato M, Klug J (2000) Steroid hormone receptors: an update. Hum Reprod Update 6:225–236PubMedCrossRef

Charmandari E, Chrousos GP, Ichijo T et al (2005) The human glucocorticoid receptor (hGR) beta isoform suppresses the transcriptional activity of hGRalpha by interfering with formation of active coactivator complexes. Mol Endocrinol 19:52–64PubMedCrossRef

10.

Schmidt S, Rainer J, Ploner C et al (2004) Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 11:45–55CrossRef

11.

Ladányi A, Tímár J, Paku S et al (1990) Selection and characterization of human melanoma lines with different liver-colonizing capacity. Int J Cancer 46:456–461PubMedCrossRef

12.

Ladányi A, Tímár J, Bocsi J et al (1995) Sex-dependent liver metastasis of human melanoma lines in SCID mice. Melanoma Res 5:83–86PubMedCrossRef

13.

Berki T, Kumánovics G, Kumánovics A et al (1998) Production and flow cytometric application of a monoclonal anti-glucocorticoid receptor antibody. J Immunol Methods 214:19–27PubMedCrossRef

14.

Martin A, Clynes M (1993) Comparison of 5 microplate colorimetric assays for in vitro cytotoxicity testing and cell proliferation assays. Cytotechnology 11:49–58PubMedCrossRef

15.

Bhakoo HS, Milholland RJ, Lopez R et al (1981) High incidence and characterization of glucocorticoid receptors in human malignant melanoma. J Natl Cancer Inst 66:21–25PubMed

16.

Maksymowych AB, Robertson NM, Litwack G (1993) Efficacy of pyridoxal treatment in controlling the growth of melanomas in cell culture and an animal pilot study. Anticancer Res 13:1925–1937PubMed

17.

Horn D, Buzard RL (1981) Growth inhibition by glucocorticoids in RPMI 3460 melanoma cells. Cancer Res 41:3155–3160PubMed

18.

Bregman MD, Peters E, Sander D et al (1983) Dexamethasone, prostaglandin A, and retinoic acid modulation of murine and human melanoma cells grown in soft agar. J Natl Cancer Inst 71:927–932PubMed

19.

Osman AM, Jansen PW, Smets LA et al (1985) Glucocorticoid receptors and cell cycle progression in human melanoma cell lines. J Cell Physiol 125:306–312PubMedCrossRef

20.

Hawkins EF, Hutchens TW, Fligiel S et al (1982) Glucocorticoids and melanoma: receptor properties of dexamethasone sensitive and resistant tumors. J Steroid Biochem 16:673–681PubMedCrossRef

21.

Rinehart J, Keville L, Neidhart J et al (2003) Hematopoietic protection by dexamethasone or granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients treated with carboplatin and ifosfamide. Am J Clin Oncol 26:448–458PubMedCrossRef

22.

Wang H, Li M, Rinehart JJ et al (2004) Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin Cancer Res 10:1633–1644PubMedCrossRef

23.

Rofstad EK, Tunheim SH, Mathiesen B et al (2002) Pulmonary and lymph node metastasis is associated with primary tumor interstitial fluid pressure in human melanoma xenografts. Cancer Res 62:661–664PubMed

24.

Banciu M, Metselaar JM, Schiffelers RM et al (2008) Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice. J Steroid Biochem Mol Biol 111:101–110PubMedCrossRef

25.

Herr I, Ucur E, Herzer K et al (2003) Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res 63:3112–3120PubMed

26.

Zhang C, Beckermann B, Kallifatidis G et al (2006) Corticosteroids induce chemotherapy resistance in the majority of tumour cells from bone, brain, breast, cervix, melanoma and neuroblastoma. Int J Oncol 29:1295–1301PubMed

27.

Zhang C, Wenger T, Mattern J et al (2007) Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors. Cancer Biol Ther 6:278–287PubMedCrossRef

28.

Jensen AØ, Thomsen HF, Engebjerg MC et al (2008) Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin’s lymphoma: a population-based case-control study. Br J Cancer 100:200–205PubMedCrossRef

29.

Collinson FJ, Lam TK, Bruijn WM et al (2008) Long-term survival and occasional regression of distant melanoma metastases after adrenal metastasectomy. Ann Surg Oncol 15:1741–1749PubMedCrossRef

30.

Helmbach H, Sinha P, Schadendorf D (2003) Human melanoma: drug resistance. Recent Results Cancer Res 161:93–110PubMed

31.

Soengas MS, Lowe SW (2003) Apoptosis and melanoma chemoresistance. Oncogene 22:3138–3151PubMedCrossRef

Titel: Glucocorticoid Receptor Expression and Antiproliferative Effect of Dexamethasone on Human Melanoma Cells
verfasst von: Judit Dobos
István Kenessey
József Tímár
Andrea Ladányi
Publikationsdatum: 01.09.2011
Verlag: Springer Netherlands
Erschienen in: Pathology & Oncology Research / Ausgabe 3/2011
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-011-9377-8

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Glucocorticoid Receptor Expression and Antiproliferative Effect of Dexamethasone on Human Melanoma Cells

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Extracellular Matrix Metalloproteinase Inducer is a Negative Prognostic Factor of Pediatric Medulloblastoma

Cellular and Molecular Mechanisms in the Two Major Forms of Inflammatory Bowel Disease

Female Breast Cancer Status According to ER, PR and HER2 Expression: A Population Based Analysis

Estrogen Receptor Alpha Expression in Ovarian Cancer Predicts Longer Overall Survival

Study of the Differentially Expressed Genes in Pleomorphic Adenoma Using cDNA Microarrays

The Evaluation of CD99 Immunoreactivity and EWS/FLI1 Translocation by Fluorescence in situ Hybridization in Central PNETs and Ewing’s Sarcoma Family of Tumors

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie